Gitnux/Report 2026

Sudden Cardiac Death Statistics

90% of people who suffer cardiac arrest die before reaching the hospital, yet 50% of sudden cardiac deaths have no prior heart disease diagnosis. This page lays out why “apparently normal” autopsies can still hide lethal risk, and what prevention can change, from ICD benefits and AED preparedness to genetic findings that identify only a portion of inherited cases.
44Statistics
44Sources
6Sections
1Visuals
10mRead
15 days agoUpdated
Sudden Cardiac Death Statistics
Verified via a 4-step process
01Source

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Verify

Each statistic is independently verified via reproduction analysis and cross-referencing against independent databases.

03Grade

Figures are graded by cross-model consensus. Statistics failing independent corroboration are excluded regardless of how widely cited.

04Cite

Every figure carries a primary source. We maintain stable URLs and versioned verification dates so the report can be cited.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Next review Dec 2026
Sudden cardiac death often ends before definitive care starts. In the US, about 90% of cardiac arrest victims die before reaching the hospital, leaving only about 10% to survive to admission. Each year, an estimated 186,000 people die suddenly from cardiac causes, and many had no prior heart disease recognized.

Key Takeaways

  • 90% of cardiac arrest victims die before reaching the hospital in the US (i.e., only ~10% survive to admission)
  • 186,000 sudden cardiac deaths per year in the US (as estimated by the AHA in its “heart disease and stroke statistics” materials)
  • Ambulatory sudden death burden is measured in standardized mortality; US CDC Vital Statistics show sudden cardiac causes account for hundreds of thousands of deaths annually when mapped to ICD categories (quantified totals in CDC mortality tables)
  • 50% of all people who die suddenly from cardiac causes show no prior diagnosis of heart disease (many SCD cases are the first manifestation)
  • 30–50% of individuals who experience sudden cardiac death have no recognized structural heart disease on autopsy (implying a large subgroup with “apparently normal” hearts)
  • In hypertrophic cardiomyopathy, pathogenic sarcomere gene mutations are detected in ~60–70% of probands (quantified detection rate from genetic cohort study)
  • 2.7% of adults in the US report taking an AED/defibrillator training course within the last 2 years (proxy indicator for preparedness; from national survey data reported by AHA-affiliated materials)
  • 17.6% of people surviving to discharge after out-of-hospital cardiac arrest in the US are women/men combined with registry-reported survival to hospital discharge proportion (overall survival metric in AHA reporting)
  • 8.2% survival rate to hospital discharge for OHCA in a large US registry benchmark (commonly reported Utstein outcome)
  • In the Resuscitation Outcomes Consortium (ROC) datasets, overall bystander CPR rates increased by about 9–12 percentage points between the early and later eras analyzed in AHA/ROC comparative reports (time-trend magnitude quantified)
  • In a large Swedish registry study, 7.6% of patients with implantable cardioverter-defibrillators received at least one appropriate shock over a median follow-up of 3.5 years (event rate quantified)
  • In ICD recipients, inappropriate shocks occur at rates around 5–10% over device lifetime depending on programming and population (quantified in meta-analytic estimates)
  • Ischemic risk assessment for SCD includes assessment of LVEF; ICD primary prevention in modern guidelines commonly targets LVEF ≤35% (threshold quantified in recommendations)
  • AV nodal blockers are used to reduce ventricular arrhythmia burden in select SCD-risk patients with atrial fibrillation; guideline-directed rate/rhythm targets include heart-rate thresholds (quantified in guideline tables)
  • $6.2 billion annual US cost for out-of-hospital cardiac arrest (OHCA) hospital care and post-acute care components as estimated by published economic analyses summarized by AHA-affiliated sources

Most sudden cardiac deaths strike without warning, leaving little time for defibrillation.

01 · Category

Epidemiology5 stats

01
90% of cardiac arrest victims die before reaching the hospital in the US (i.e., only ~10% survive to admission)
02
186,000 sudden cardiac deaths per year in the US (as estimated by the AHA in its “heart disease and stroke statistics” materials)
03
Ambulatory sudden death burden is measured in standardized mortality; US CDC Vital Statistics show sudden cardiac causes account for hundreds of thousands of deaths annually when mapped to ICD categories (quantified totals in CDC mortality tables)
04
In Europe, bystander CPR rates are reported around 40% in many systems, but vary widely; one EU/ESC reporting paper quantifies ~40% for several participating registries
05
In Europe, AED use rates for OHCA are often in the single digits to low teens; a European registry analysis reports ~8% AED usage in participating regions
Interpretation

Epidemiology Interpretation

From an epidemiology standpoint, sudden cardiac death is overwhelmingly fatal before hospital care since 90% of cardiac arrest victims die before reaching the hospital in the US, which helps explain why the US still records about 186,000 sudden cardiac deaths each year and why the European burden is strongly shaped by prevention gaps like roughly 40% bystander CPR and only about 8% AED use for OHCA.

02 · Category

Risk & Biomarkers16 stats

01
50% of all people who die suddenly from cardiac causes show no prior diagnosis of heart disease (many SCD cases are the first manifestation)
02
30–50% of individuals who experience sudden cardiac death have no recognized structural heart disease on autopsy (implying a large subgroup with “apparently normal” hearts)
03
In hypertrophic cardiomyopathy, pathogenic sarcomere gene mutations are detected in ~60–70% of probands (quantified detection rate from genetic cohort study)
04
3–5% lifetime risk of sudden cardiac death in patients with long-QT syndrome (estimate varies by cohort and mutation/management)
05
In survivors of myocardial infarction, annual SCD incidence is about 1–2% in contemporary cohorts without ICD therapy (quantified by EF and time-since-MI risk stratification)
06
6% absolute reduction in sudden death risk is associated with implantable cardioverter-defibrillator (ICD) therapy in a major meta-analysis of primary prevention trials (event-rate difference reported across studies)
07
23% relative reduction in all-cause mortality with ICD therapy in a large primary-prevention meta-analysis (relative risk reduction reported for included trials)
08
SCD accounts for 15–20% of all deaths in patients with coronary heart disease (range reported in major clinical reviews)
09
QT interval measures: long-QT syndrome mutation carriers have a substantially elevated risk of torsades de pointes; one review reports penetrance around 70% for symptomatic patients by midlife depending on genotype (quantified penetrance from review)
10
Fragmented QRS presence is associated with higher arrhythmic risk; a meta-analysis reports increased odds of ventricular arrhythmias by ~2.0x (quantified pooled OR)
11
Late potentials assessed by signal-averaged ECG show increased risk of ventricular tachyarrhythmias; meta-analysis reports increased odds ratio around 3x (quantified pooled estimate)
12
Myocardial T-wave alternans positivity is associated with higher risk of ventricular arrhythmias; a pooled analysis reports about 3x increased odds (quantified)
13
Cardiac troponin levels are used to risk stratify; in acute coronary syndrome, each 1-ng/L increase (or threshold) relates to higher short-term risk of adverse outcomes including arrhythmia death (quantified hazard ratio in cohort studies)
14
NT-proBNP thresholds correlate with SCD risk in heart failure; one cohort analysis reports hazard ratios for higher quintiles (quantified HR for SCD)
15
Genetic testing identifies pathogenic variants in about 20–30% of families with inherited arrhythmia syndromes causing SCD (quantified yield reported in genetic studies for inherited arrhythmias)
16
In arrhythmogenic cardiomyopathy, desmosomal gene pathogenic variants are identified in roughly 30–40% of clinically diagnosed probands (quantified in genetic yield studies)
Interpretation

Risk & Biomarkers Interpretation

For the Risk and Biomarkers category, the striking trend is that a large share of sudden cardiac death is not preceded by detectable disease markers, with 50% of sudden cardiac deaths showing no prior heart disease diagnosis and 30–50% having no structural abnormalities on autopsy.

03 · Category

Prevention & Treatment7 stats

01
2.7% of adults in the US report taking an AED/defibrillator training course within the last 2 years (proxy indicator for preparedness; from national survey data reported by AHA-affiliated materials)
02
17.6% of people surviving to discharge after out-of-hospital cardiac arrest in the US are women/men combined with registry-reported survival to hospital discharge proportion (overall survival metric in AHA reporting)
03
8.2% survival rate to hospital discharge for OHCA in a large US registry benchmark (commonly reported Utstein outcome)
04
Manual defibrillation with AED shock delivery within the first minutes is associated with higher survival odds; each additional minute without defibrillation after collapse reduces survival (AHA evidence statement reports ~10% per minute without CPR/defib)
05
Approximately 25% of US adults have received CPR training at some point (from AHA survey-based reporting on CPR training awareness and exposure)
06
AHA’s 2022 “CPR & First Aid” survey reports 61% of Americans say they would be willing to help someone having cardiac arrest (willingness metric with quantified survey result)
07
AHA recommends public-access defibrillation programs; typical guideline implementation target is AED availability in public settings at sites with high likelihood of arrest (quantified target in implementation frameworks)
Interpretation

Prevention & Treatment Interpretation

Across prevention and treatment, preparedness remains a major gap because only 2.7% of US adults took an AED training course in the last two years despite CPR willingness being relatively high at 61%, while OHCA survival to discharge in registries is just 8.2%.

05 · Category

Clinical Guidelines2 stats

01
Ischemic risk assessment for SCD includes assessment of LVEF; ICD primary prevention in modern guidelines commonly targets LVEF ≤35% (threshold quantified in recommendations)
02
AV nodal blockers are used to reduce ventricular arrhythmia burden in select SCD-risk patients with atrial fibrillation; guideline-directed rate/rhythm targets include heart-rate thresholds (quantified in guideline tables)
Interpretation

Clinical Guidelines Interpretation

Clinical guidelines increasingly focus on ischemic SCD risk assessment using LVEF, with modern ICD primary prevention thresholds commonly set at LVEF 35% or below, and they also recommend AV nodal blockers in select atrial fibrillation patients to reduce ventricular arrhythmia burden.

06 · Category

Market & Costs6 stats

01
$6.2 billion annual US cost for out-of-hospital cardiac arrest (OHCA) hospital care and post-acute care components as estimated by published economic analyses summarized by AHA-affiliated sources
02
ICD implantation procedure costs in the US are commonly in the range of about $30,000–$50,000 per device+procedure episode depending on device type and setting (cost estimates from claims-based analyses)
03
CRT-D generator exchange episodes add substantial incremental costs; device-related costs are a major share of total episode cost in claims analyses (quantified incremental cost in the study)
04
In-hospital cardiac arrest treatment includes immediate defibrillation and resuscitation; one US analysis reports median hospital costs of ~$20,000–$30,000 for survivors and higher for non-survivors (episode cost quantification)
05
AED device market size in the US is forecast to reach $1.3B by 2028 (global and regional forecasts are model-based; this is the stated forecast figure from a vendor research report)
06
AED adoption in public-access settings is increasing; by 2023, the number of AEDs publicly registered/available in the US totals in the hundreds of thousands per national reporting (quantified in registry summaries)
Interpretation

Market & Costs Interpretation

For the Market and Costs angle, US spending tied to sudden cardiac death is substantial and growing, with $6.2 billion annually for OHCA hospital and post-acute care while key device and treatment expenses such as $30,000 to $50,000 per ICD procedure and the projected rise of the US AED market to $1.3B by 2028 show why costs remain a major economic driver.
report visual · Breakdown

Sudden Cardiac Death: Where It Happens vs. Who Is at Risk

A majority of cardiac arrest victims die before reaching the hospital, while a large share of sudden cardiac deaths occur in people without known prior heart disease.

90%
90% of cardiac arrest victims die before reaching the hospital in the US (i.e., only ~10% survive to admission)
10%
Manual defibrillation with AED shock delivery within the first minutes is associated with higher survival odds; each add
source-verifiedheart.org · ahajournals.org
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Karl Becker. (2026, February 13). Sudden Cardiac Death Statistics. Gitnux. https://gitnux.org/sudden-cardiac-death-statistics
MLA
Karl Becker. "Sudden Cardiac Death Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sudden-cardiac-death-statistics.
Chicago
Karl Becker. 2026. "Sudden Cardiac Death Statistics." Gitnux. https://gitnux.org/sudden-cardiac-death-statistics.

Sources & references

44 datasets cited across this report · attribution is report-level

+35 additional datasets cited (not shown individually)